Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3 Open-label Extension (OLE) Study to Evaluate the Long-term Safety and Efficacy of Ralinepag in Subjects With World Health Organization (WHO) Group 1 Pulmonary Arterial Hypertension (PAH)

NCT03683186 is registered in ClinicalTrials.gov with United Therapeutics as lead sponsor.

NCT NCT03683186
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03683186 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3 Open-label Extension (OLE) Study to Evaluate the Long-term Safety and Efficacy of Ralinepag in Subjects With World Health Organization (WHO) Group 1 Pulmonary Arterial Hypertension (PAH)
Lead sponsor
United Therapeutics
Phase
Phase 3
Overall status
Enrolling by invitation
Start date
September 23, 2019
Completion date
December 31, 2026
Enrollment
1,000 (estimated)
Sites
190

Conditions

As the registry lists them; a condition with its own page is linked.

cardiovascular diseases, connective tissue diseases, familial primary pulmonary hypertension, hypertension, hypertension, pulmonary, lung diseases, pah, pulmonary arterial hypertension, pulmonary hypertension, respiratory tract disease, vascular diseases